Uro-Vaxom in immunoprophilaxis and immunotherapy of recurrent urinary tract infections

Abstract:

In early 2011, the drug OM -89 was authorized in Croatia under the brand name of Uro-Vaxom. It consists of immunostimulating fractions extracted from 18 different serotypes of Escherichia coli (E. coli). Each serotype has been specially cultured, inactivated, fractionated and then purified and lyophilized. OM -89 is supplied as gelatine capsules of 6 mg of E. coli lyophilized lysate for oral use. The drug was tested in many clinical trials including approximately 2000 subjects. It proved to have a stimulating effect on immune defence mechanisms and to significantly reduce the incidence of recurrent urinary tract infections, duration and severity of infection symptoms, the incidence of bacteriuria and leukocyturia and the need for antimicrobial drugs. It is well tolerated and has low incidence of side effects. Uro-Vaxom is the only immunostimulating drug recommended by the European Association of Urology for immunoprophylaxis of recurrent uncomplicated urinary tract infections in women. Uro-Vaxom is primarily recommended for prevention of uncomplicated urinary tract infections of the lower urinary tract in women and as concomitant therapy in the antimicrobial treatment of acute urinary tract infections. 

Key words:
Escherichia coli; immunization; immunotherapy; OM -89; urinary tract infections